TrialBritish journal of clinical pharmacology2018

Single- and multiple-dose pharmacokinetics and safety of pimodivir, a novel, non-nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open-label study in healthy volunteers.

Sofie Deleu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.